Rhythm Biosciences Ltd has released a press release.
Non-renounceable rights issue Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Placement & Rights Offer to raise approximately $6 million
- COVID-19 Update
- Successful ISO13485 Surveillance Audit
- Rhythm Successfully Validates Key Biomarker
- Rhythm Biosciences Granted China Patent
Later from Rhythm Biosciences
- Addtl Clinical Trial Site Signed - First Patient Recruited
- Revised CEO Contract and LTIP initiated for all employees
- Revised CEO Contract and LTIP for all employees - amended
- Rhythm Successfully Validates Two Adjunct Biomarkers
- New Clinical Trial Site Contracted and Recruiting
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences